Passions

Sports

CrossFit

Concerts

 

Experience

Abivax Announces $235.8 Million IPO

October 20, 2023

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Read more

Related contacts

Div Gupta
Partner, New York
Marc Recht
Partner, Boston
Ryan Sansom
Partner, Boston
Denny Won
Partner, San Francisco
Aaron Pomeroy
Partner, Colorado
Richard Segal
Partner, New York
Nyron J. Persaud
Partner, New York
Madhuri Roy
Partner, Palo Alto
Courtney Thorne
Partner, Boston
Elizabeth Anne Wright
Partner, Brussels
Xander Lee
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Stephanie Gentile
Partner, New York
Kevin King
Partner, Washington, DC
Katie Kazem
Partner, Reston
Natasha Leskovsek
Of Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Minkyu Park
Associate, New York
Jesse Schulman
Associate, Washington, DC
Barry Kuang
Associate, Boston
Olivia Creser
Associate, New York
Peter A. Haddad
Associate, San Diego
Samuel Paullin
Associate, Chicago
Evan Leitner
Associate, New York
Rick Jantz
Associate, Los Angeles Santa Monica
Cara Buchicchio
Associate, New York
Jason Valentine
Associate, Washington, DC
Jessica Koffel
Associate, Brussels
Mor Agam
Associate, New York
Cathy Rude
Paralegal Specialist, Boston

Related Practices & Industries

Vistagen Therapeutics – $100 Million Follow-on Offering of Common Stock, Pre-Funded Warrants and Two Tranches of Common Stock Warrants

October 4, 2023

Cooley advised the underwriters in Vistagen Therapeutics’ $100 million follow-on offering of common stock, pre-funded warrants, and two tranches of common stock warrants, with Jefferies, Stifel and William Blair acting as lead book-running managers. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders. Partners Denny Won, Charlie Kim and Courtney Tygesson led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Charlie Kim
Partner, San Diego
Courtney M.W. Tygesson
Partner, Chicago
Christine Turner
Associate, Colorado
Jesse Schulman
Associate, Washington, DC
Mike Lam
Associate, Los Angeles Santa Monica
Carley Cruea
Associate, Washington, DC

Related Practices & Industries

Neumora Therapeutics – $250.1 Million IPO

September 15, 2023

Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Read more

Related contacts

Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
David Peinsipp
Partner, San Francisco
Denny Won
Partner, San Francisco
Grady Chang
Associate, Los Angeles Santa Monica
Madison (JJ) Meng
Associate, San Francisco
Kyle Huh
Associate, Palo Alto
Peter A. Haddad
Associate, San Diego
Heidi Ausman
Senior Paralegal, San Diego
Lila Hope
Partner, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Mika Reiner Mayer
Partner, Palo Alto
Barbara Mirza
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Jennifer Raab
Partner, Palo Alto
Madhuri Roy
Partner, Palo Alto
Erica Russell
Associate, San Francisco
Randy Sabett
Special Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Karen Tsai
Special Counsel, Washington, DC
Francis Wheeler
Partner, Colorado
Mark Windfeld-Hansen
Senior Counsel, Palo Alto

Related Practices & Industries

Merus – $172.5 Million Follow-on Offering

August 14, 2023

Cooley advised the underwriters in Merus’ $172.5 million follow-on offering. Jefferies, BofA Securities, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. Merus is a clinical-stage oncology company developing innovative, full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Partners Denny Won, Courtney Thorne and Div Gupta led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Courtney Thorne
Partner, Boston
Div Gupta
Partner, New York
Evan Leitner
Associate, New York
David D. Kim
Associate, San Francisco
Charles York
Associate, New York
Kindall G. Jackson
Associate, Washington, DC
Peter A. Haddad
Associate, San Diego

Related Practices & Industries

Sagimet Biosciences Announces Upsized $85 Million IPO

July 18, 2023

Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million.

Read more

Related contacts

John McKenna
Partner, Palo Alto
Natalie Karam
Partner, Palo Alto
Denny Won
Partner, San Francisco
Heidi A. Erlacher
Partner, Boston
Natasha Leskovsek
Of Counsel, Washington, DC
David D. Kim
Associate, San Francisco
Mike Lam
Associate, Los Angeles Santa Monica
Victoria Comesañas
Associate, Palo Alto
Thomas "TJ" Paxton
Associate, Boston
Kate Walther
Paralegal Specialist, San Diego

Related Practices & Industries

View more

Rankings & accolades

Chambers USA: Up and Coming – Capital Markets: Debt & Equity (California and Nationwide – Western United States) (2023)

Chambers USA: Associate to Watch – Capital Markets: Debt & Equity (California and Nationwide – Western United States) (2021-2022)

 

Memberships & affiliations

New York State Bar Association

Denny has an amazing work ethic and he provides seamless, flawless execution on extremely tight timelines.

Chambers USA